Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000591 | 0.90 | P2RY1 (0.50) | P2RY1P2RX3P2RX1P2RX4ENPP1 | |
| SCHEMBL13591525 | 0.87 | ADORA1 (0.35) | — | |
| SCHEMBL16777548 | 0.83 | POLA1 (0.53) | P2RY1P2RX3P2RX1P2RX4ENPP1 | |
| SCHEMBL16777344 | 0.83 | POLA1 (0.53) | P2RY1P2RX3P2RX1P2RX4ENPP1 | |
| SCHEMBL16000597 | 0.83 | POLB (0.51) | P2RY1P2RX3P2RX1P2RX4ENPP1 | |
| SCHEMBL16081063 | 0.83 | P2RY1 (0.51) | P2RY1P2RX3P2RX1P2RX4ENPP1 | |
| SCHEMBL23584290 | 0.83 | ADORA2A (0.41) | — | |
| SCHEMBL16000602 | 0.83 | ADORA2A (0.41) | — | |
| SCHEMBL16003080 | 0.83 | P2RX3 (0.60) | P2RY1P2RX3P2RX1P2RX4P2RY11 | |
| SCHEMBL17617926 | 0.82 | P2RY1 (0.49) | P2RY1P2RX3P2RX1P2RX4ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309275-B2 | 3′-deoxy nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309275-B2 | 3′-deoxy nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140248241-A1 | 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2014-09-04 | — | — | US | disclosed |
| US-20140248241-A1 | 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248241-A1 | 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV | SLC29A1, NUDT1, SLC28A1 | P2RY1 168/4885P2RX3 739/4885P2RX1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.